Why Edwards Lifesciences (EW) Is On Investors’ Radar Today

Edwards Lifesciences (EW) is drawing attention after a period where the stock showed a mix of modest short term declines and a stronger 1 year total return. This performance is prompting some market participants to reassess its recent results and characteristics.

At a share price of US$83.46, Edwards Lifesciences has seen its short term share price momentum cool, with a 1 day decline of 1.06% and a 30 day share price return showing a 2.57% decline. Its 1 year total shareholder return of 19.28% points to stronger underlying support over a longer horizon as investors reassess growth prospects and risk around its cardiovascular portfolio.

If Edwards Lifesciences has you looking closer at medical names, it could be a good time to scan other opportunities across healthcare stocks for fresh ideas.

With revenue and net income growth in the high single to low double digits, and the stock trading around US$83, the question is whether Edwards Lifesciences still trades at a discount or if the market is already pricing in future growth.

Price-to-Earnings of 36.1x: Is it justified?

At the last close of US$83.46, Edwards Lifesciences trades on a P/E of 36.1x, which places it at a premium to both its industry and peer averages.

The P/E multiple compares the current share price to earnings per share. A higher P/E often reflects stronger growth expectations or a willingness to pay up for a company’s profitability profile. For a medical equipment company like Edwards Lifesciences, investors often look at the P/E to judge how much future earnings growth and product demand the market is already factoring in.

In this case, the 36.1x P/E sits above the US Medical Equipment industry average of 31.2x and also above the peer average of 32.4x, suggesting the market is assigning Edwards Lifesciences a premium earnings tag. Compared to an estimated fair P/E of 31.8x, the current level also sits higher than where the market could potentially settle if expectations cool or re-rate.

Result: Price-to-Earnings of 36.1x (OVERVALUED)

However, a premium P/E of 36.1x, alongside a 5 year total return of a 3.56% decline and recent short term share price weakness, could challenge this optimistic setup.

Another View: What Our DCF Says

While the 36.1x P/E paints Edwards Lifesciences as expensive versus industry, peers, and even its own fair ratio of 31.8x, our DCF model points to a different conclusion. The shares are trading about 3.1% below an estimated fair value of US$86.14. So which signal matters more for you?

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Edwards Lifesciences for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 878 undervalued stocks based on their cash flows. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Build Your Own Edwards Lifesciences Narrative

If you see the numbers differently or prefer to dig into the data yourself, you can build your own Edwards Lifesciences view in minutes by starting with Do it your way.

A great starting point for your Edwards Lifesciences research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.

Looking for more investment ideas?

If Edwards Lifesciences has sharpened your focus, do not stop here, broaden your watchlist now so you are not the one hearing about opportunities later.

• Spot potential value early by checking out these 3532 penny stocks with strong financials that already pair tiny share prices with stronger financial foundations.
• Explore automation and data trends by scanning these 23 AI penny stocks that influence how AI is used in real businesses.
• Strengthen your income toolkit by filtering for these 13 dividend stocks with yields > 3% that may offer more consistent cash returns.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.